KaNDy Therapeutics

KaNDy Therapeutics, established in 2017, is a UK-based clinical-stage company dedicated to optimizing the potential of its unique NK-1,3 receptor antagonist NT-814 in treating common chronic debilitating female sex hormone-related conditions.